Market research
CFMS ConforMIS Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 2.27
- Dividend yield
- 0.0%
- Beta
- 1.42
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US20717E1010
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 2.27
- Dividend yield
- 0.0%
- Beta
- 1.42
About
About ConforMIS Inc
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Brazil, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CFMS discussion.
5 years, 4 months ago
Conformis, Inc is currently in a long term uptrend where the price is trading 15.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Conformis, Inc's total revenue sank by 16.0% to $17M since the same quarter in the previous year.
Its net income has dropped by 21.9% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 17.0% to $-4M since the same quarter in the previous year.
Based on the above factors, Conformis, Inc gets an overall score of 3/5.